Suppr超能文献

处理移植肾功能衰竭:应对复杂情况。

Managing the failing renal allograft: navigating a complex topography.

作者信息

Kendrick Elizabeth A

机构信息

David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States.

出版信息

Front Nephrol. 2025 Jun 5;4:1223114. doi: 10.3389/fneph.2024.1223114. eCollection 2024.

Abstract

Recipients of kidney transplants often outlive the function of the renal allograft will need ESRD management. Patients face a higher risk of mortality in the period of transition from failing allograft to dialysis. Long term risk of cardiovascular complications and risk of infections and cancer with use of long-term immune suppression contribute to poor outcomes. Patients with failing transplants appear to have poorer control of CKD complications and are more likely to initiate hemodialysis using a catheter. Outcomes of peritoneal dialysis in the setting of the failing allograft in general are equivalent to hemodialysis. Management of these patients in transplant center clinics specifically focused on patients with failing allografts may have benefit, but maximal utility has yet to be demonstrated. Patients with failed transplants can have a survival benefit with retransplant, even in older patients. There may not be a benefit to retransplant in patients older than 70 years of age. Patients with failing renal grafts should be assessed as to whether they are potential candidates for retransplant prior to needing to start dialysis to allow for identification of a living kidney donor or to be listed as soon a possible on the kidney transplant wait list as to minimize the wait time on dialysis. Decisions regarding reduction of immunosuppression once the patient has started dialysis should be made with guidance from the transplant center in the context of patient-centric factors such as candidacy for retransplant and minimizing complications of long-term immunosuppression.

摘要

肾移植受者的生存期往往会超过同种异体肾移植的功能期,届时将需要进行终末期肾病管理。在从移植肾失功过渡到透析的阶段,患者面临更高的死亡风险。长期免疫抑制导致的心血管并发症风险、感染风险和癌症风险,都使得预后较差。移植肾失功的患者似乎对慢性肾病并发症的控制更差,并且更有可能使用导管开始血液透析。在移植肾失功的情况下,腹膜透析的总体效果与血液透析相当。在专门针对移植肾失功患者的移植中心诊所对这些患者进行管理可能会有好处,但尚未证明其最大效用。移植肾失功的患者即使是老年患者,再次移植也可能有生存益处。对于70岁以上的患者,再次移植可能没有益处。在需要开始透析之前,应评估移植肾失功的患者是否为再次移植的潜在候选人,以便确定活体肾供体,或者尽快列入肾移植等待名单,以尽量缩短透析等待时间。一旦患者开始透析,关于减少免疫抑制的决定应在移植中心的指导下,结合以患者为中心的因素做出,如再次移植的候选资格以及尽量减少长期免疫抑制的并发症。

相似文献

1
Managing the failing renal allograft: navigating a complex topography.处理移植肾功能衰竭:应对复杂情况。
Front Nephrol. 2025 Jun 5;4:1223114. doi: 10.3389/fneph.2024.1223114. eCollection 2024.
9
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.

本文引用的文献

8
Waiting Time for Second Kidney Transplantation and Mortality.第二次肾移植等待时间与死亡率。
Clin J Am Soc Nephrol. 2022 Jan;17(1):90-97. doi: 10.2215/CJN.07620621. Epub 2021 Dec 29.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验